TI
MYGN icon

Turner Investments’s Myriad Genetics MYGN Stock Holding History

Turner Investments’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-24,790
Closed -$510K – 282
2016
Q3 		$510K Buy
+24,790
New +$629K 0.17% 141

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Turner Investments's MYGN Position: Q4 2016 in Review

Turner Investments sold out of Myriad Genetics (MYGN) in Q4 2016, closing a stake of 24,790 shares — an estimated $510K sold.

Turner Investments first reported a position in MYGN in Q3 2016 and held it in 1 quarter. The position peaked at $510K in Q3 2016. 223 funds tracked by Wall St. Rank hold MYGN as of Q4 2016.

  • Turner Investments reported no remaining Myriad Genetics position as of Q4 2016 after selling out during the quarter.
  • Turner Investments sold 24,790 Myriad Genetics shares in Q4 2016, an estimated $510K.
  • Turner Investments first reported a position in Myriad Genetics in Q3 2016 and held it in 1 quarter.
  • Turner Investments's Myriad Genetics position peaked at $510K in Q3 2016.
  • 223 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2016.

Based on Turner Investments's 13F filing for Q4 2016, filed 8 Feb 2017.